Literature DB >> 29720397

Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.

Virginie Grouthier1, Benedicte Lebrun-Vignes2, Andrew M Glazer3, Philippe Touraine1, Christian Funck-Brentano2, Antoine Pariente4, Carine Courtillot1, Anne Bachelot1, Dan M Roden3, Javid J Moslehi3, Joe-Elie Salem2,3.   

Abstract

OBJECTIVE: A prolonged QTc (LQT) is a surrogate for the risk of torsade de pointes (TdP). QTc interval duration is influenced by sex hormones: oestradiol prolongs and testosterone shortens QTc. Drugs used in the treatment of breast cancer have divergent effects on hormonal status.
METHODS: We performed a disproportionality analysis using the European database of suspected adverse drug reaction (ADR) reports to evaluate the reporting OR (ROR χ2) of LQT, TdP and ventricular arrhythmias associated with selective oestrogen receptor modulators (SERMs: tamoxifen and toremifene) as opposed to aromatase inhibitors (AIs: anastrozole, exemestane and letrozole). When the proportion of an ADR is greater in patients exposed to a drug (SERMs) compared with patients exposed to control drug (AIs), this suggests an association between the specific drug and the reaction and is a potential signal for safety. Clinical and demographic characterisation of patients with SERMs-induced LQT and ventricular arrhythmias was performed.
RESULTS: SERMs were associated with higher proportion of LQT reports versus AIs (26/8318 vs 11/14851, ROR: 4.2 (2.11-8.55), p<0.001). SERMs were also associated with higher proportion of TdP and ventricular arrhythmia reports versus AIs (6/8318 vs 2/14851, ROR: 5.4 (1.29-26.15), p:0.02; 16/8318 vs 12/14851, ROR: 2.38 (1.15-4.94), p:0.02, respectively). Mortality was 38% in patients presenting ventricular arrhythmias associated with SERMs.
CONCLUSIONS: SERMs are associated with more reports of drug-induced LQT, TdP and ventricular arrhythmias compared with AIs. This finding is consistent with oestradiol-like properties of SERMs on the heart as opposed to effects of oestrogen deprivation and testosterone increase induced by AIs. TRIAL REGISTRATION NUMBER: NCT03259711. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Long QT syndrome; aromatase inhibitors; selective estrogen receptor modulators; sex steroid hormones; torsade de pointes; ventricular arrhythmias

Mesh:

Substances:

Year:  2018        PMID: 29720397      PMCID: PMC8022857          DOI: 10.1136/heartjnl-2017-312934

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  25 in total

Review 1.  The reporting odds ratio and its advantages over the proportional reporting ratio.

Authors:  Kenneth J Rothman; Stephan Lanes; Susan T Sacks
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-08       Impact factor: 2.890

Review 2.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

Review 3.  Endocrine treatment in breast cancer: Cure, resistance and beyond.

Authors:  Konstantinos Tryfonidis; Dimitrios Zardavas; Benita S Katzenellenbogen; Martine Piccart
Journal:  Cancer Treat Rev       Date:  2016-09-07       Impact factor: 12.111

4.  Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes.

Authors:  Jianying He; Margaret E Kargacin; Gary J Kargacin; Christopher A Ward
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-04-17       Impact factor: 4.733

5.  Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species.

Authors:  Thomas O'Hara; Yoram Rudy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-09       Impact factor: 4.733

6.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.

Authors:  M L De Bruin; M Pettersson; R H B Meyboom; A W Hoes; H G M Leufkens
Journal:  Eur Heart J       Date:  2005-01-06       Impact factor: 29.983

Review 7.  The cardiovascular effects of selective estrogen receptor modulators.

Authors:  G E Christodoulakos; I V Lambrinoudaki; D C Botsis
Journal:  Ann N Y Acad Sci       Date:  2006-12       Impact factor: 5.691

Review 8.  Toremifene for breast cancer: a review of 20 years of data.

Authors:  Charles L Vogel; Mary Ann Johnston; Christi Capers; Deborah Braccia
Journal:  Clin Breast Cancer       Date:  2013-10-31       Impact factor: 3.225

9.  Oral contraceptive use and the ECG: evidence of an adverse QT effect on corrected QT interval.

Authors:  Tara Sedlak; Chrisandra Shufelt; Carlos Iribarren; Liisa L Lyon; C Noel Bairey Merz
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05-03       Impact factor: 1.468

10.  Hypogonadism as a Reversible Cause of Torsades de Pointes in Men.

Authors:  Joe-Elie Salem; Xavier Waintraub; Carine Courtillot; Christian M Shaffer; Estelle Gandjbakhch; Carole Maupain; Javid J Moslehi; Fabio Badilini; Julien Haroche; Paul Gougis; Veronique Fressart; Andrew M Glazer; Francoise Hidden-Lucet; Philippe Touraine; Benedicte Lebrun-Vignes; Dan M Roden; Anne Bachelot; Christian Funck-Brentano
Journal:  Circulation       Date:  2018-07-03       Impact factor: 29.690

View more
  16 in total

Review 1.  Cardiovascular toxicity of breast cancer treatment: an update.

Authors:  Christos Papageorgiou; Angeliki Andrikopoulou; Meletios-Athanasios Dimopoulos; Flora Zagouri
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-17       Impact factor: 3.333

Review 2.  Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.

Authors:  Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

Review 3.  New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.

Authors:  Oreste Lanza; Armando Ferrera; Simone Reale; Giorgio Solfanelli; Mattia Petrungaro; Giacomo Tini Melato; Massimo Volpe; Allegra Battistoni
Journal:  Med Sci (Basel)       Date:  2022-05-25

4.  Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women.

Authors:  Joe-Elie Salem; Pauline Dureau; Anne Bachelot; Marine Germain; Pascal Voiriot; Bruno Lebourgeois; David-Alexandre Trégouët; Jean-Sébastien Hulot; Christian Funck-Brentano
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

5.  Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes.

Authors:  Joe-Elie Salem; Tao Yang; Javid J Moslehi; Xavier Waintraub; Estelle Gandjbakhch; Anne Bachelot; Francoise Hidden-Lucet; Jean-Sebastien Hulot; Bjorn C Knollmann; Benedicte Lebrun-Vignes; Christian Funck-Brentano; Andrew M Glazer; Dan M Roden
Journal:  Circulation       Date:  2019-08-05       Impact factor: 29.690

6.  When Manual Analysis of 12-Lead ECG Holter Plays a Critical Role in Discovering Unknown Patterns of Increased Arrhythmogenic Risk: A Case Report of a Patient Treated with Tamoxifen and Subsequent Pneumonia in COVID-19.

Authors:  Donatella Brisinda; Barbara Merico; Peter Fenici; Riccardo Fenici
Journal:  Cardiovasc Toxicol       Date:  2021-05-20       Impact factor: 3.231

7.  Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.

Authors:  Douglas B Johnson; Ali Manouchehri; Alexandra M Haugh; Henry T Quach; Justin M Balko; Benedicte Lebrun-Vignes; Andrew Mammen; Javid J Moslehi; Joe-Elie Salem
Journal:  J Immunother Cancer       Date:  2019-05-22       Impact factor: 13.751

8.  The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.

Authors:  Koen G A M Hussaarts; Florine A Berger; Lisette Binkhorst; Esther Oomen-de Hoop; Roelof W F van Leeuwen; Robbert J van Alphen; Daniëlle Mathijssen-van Stein; Natasja M S de Groot; Ron H J Mathijssen; Teun van Gelder
Journal:  Pharm Res       Date:  2019-12-16       Impact factor: 4.200

9.  Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.

Authors:  Joe-Elie Salem; Lee S Nguyen; Javid J Moslehi; Stéphane Ederhy; Bénédicte Lebrun-Vignes; Dan M Roden; Christian Funck-Brentano; Paul Gougis
Journal:  Eur Heart J       Date:  2021-10-07       Impact factor: 35.855

10.  Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study.

Authors:  Marta Pineda-Moncusí; Natalia Garcia-Giralt; Adolfo Diez-Perez; Ignasi Tusquets; Sonia Servitja; Joan Albanell; Daniel Prieto-Alhambra; Xavier Nogués
Journal:  Ther Adv Med Oncol       Date:  2020-03-25       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.